Brain-computer interface (BCI) technology company Synchron has acquired an equity stake in Acquandas, a specialist in high-precision components, for an undisclosed amount.
The stake acquisition is expected to bolster Synchron's position in the implantable medical device industry by integrating Acquandas' advanced shape-memory, flexible metallic components into its product offerings.
Acquandas has been developing a new generation of components, including micro-patterned Nitinol thin films that are used in medical devices.
These components are known for their miniaturised structures, high resolution, complex geometries, biocompatibility, and enhanced mechanical properties.
As part of the equity transaction, Synchron CEO and founder Tom Oxley will join the Acquandas Governance Council.
Additionally, Synchron's chief technology officer Riki Banerjee will assume the role of observer.
Oxley said: “As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces.”
Acquandas CEO and founder Dr Rodrigo Lima de Miranda said: “After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor.
“This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market.”
Synchron developed the Stentrode Endovascular Electrode Array, which can sense motor signals within a blood vessel.
Last March, Synchron initiated the COMMAND trial at the Gates Vascular Institute in Buffalo, New York, US.
The trial was an early feasibility study (EFS) that aimed to evaluate the safety and preliminary efficacy of the Synchron Switch.
Implanted through the blood vessels, this BCI device enables individuals with limited mobility to control digital technology using their thoughts.
